EastWest Bioscience Inc.

As of April 30, 2022, EastWest Bioscience Inc. has 100.66M shares outstanding.

These figures are as of April 30, 2022. The EV/Sales ratio of 8.36 reflects the premium investors pay for the company's revenue stream, a useful check when earnings are depressed or negative. EastWest Bioscience Inc. trades at an EV/FCF ratio of 147.97, comparing the total takeover cost of the business to the cash it actually generates for all capital providers.

As of April 30, 2022, EastWest Bioscience Inc. maintains a current ratio of 0.09, meaning it holds 0.1x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is 71.67, indicating elevated leverage, while an interest coverage ratio of -6.60 demonstrates limited ability to service its debt obligations.

These figures cover the twelve months ended April 30, 2022. Return on assets (ROA) stands at 2.02, measuring how efficiently the asset base is converted into earnings. Return on capital employed (ROCE) is 25.44, useful for judging operating efficiency across full business cycles. Inventory turnover of 1.27 indicates how many times EastWest Bioscience Inc. sells and replaces its inventory over a year, a key working capital efficiency ratio.

Over the twelve months ended April 30, 2022, EastWest Bioscience Inc. posted a gross margin of 9.91, reflecting its pricing power and cost economics. The operating margin of -674.22 and net profit margin of 37.23 provide insight into operational efficiency.

As of April 30, 2022, EastWest Bioscience Inc. has an Altman Z-Score of -2.47, below the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.